Search for: "DNA Diagnostics, Inc."
Results 21 - 40
of 156
Sorted by Relevance
|
Sort by Date
17 Apr 2013, 11:50 am
At issue is the patentability of isolated DNA sequences, in particular in relation to diagnostic and drug screening claims. [read post]
20 Jul 2022, 8:27 am
” She notes that ‘[s]ince Mayo, we have held every single diagnostic claim in every case before us ineligible. [read post]
3 Apr 2020, 1:04 pm
Ariosa Diagnostics, Inc. [read post]
24 Mar 2020, 1:24 am
Ariosa Diagnostics, Inc., 356 F. [read post]
23 May 2015, 10:24 pm
Two recent decisions issued by the Australian Patent Office address the requirements for extending the term of a patent encompassing a pharmaceutical substance ‘when produced by a process that involves the use of recombinant DNA technology’: ImmunoGen, Inc. [2014] APO 88 and Novartis Vaccines and Diagnostics S.r.l. [2015] APO 2.What is interesting about both these cases is that, while recombinant DNA techniques are employed in manufacturing the… [read post]
26 Jul 2010, 10:41 pm
The potential downside to this new technology is DNA profiling. [read post]
15 Jul 2015, 6:41 am
Sequenom, Inc. [read post]
25 Aug 2014, 12:07 pm
MYRIAD GENETICS, INC., ET AL. 569 U. [read post]
14 Jun 2013, 4:08 pm
Myriad Genetics, Inc., et al., 569 U.S. ___, issued June 13, 2013. [read post]
2 Oct 2023, 7:41 am
The patents at issue covers breakthrough diagnostic technique using cell-free DNA to non-invasively detect organ transplant rejection. [read post]
27 Sep 2012, 5:52 am
Plaintiff Promega Corporation ("Promega") filed an action against Life Technologies Corporation, Applied Biosystems, LLC and Invitrogen IP Holdings, Inc. for infringing and inducing infringement of five patents pertaining to copying of sequences of a DNA strand. [read post]
8 Oct 2019, 10:00 pm
Ariosa Diagnostics, Inc. than the US, finding that the method of detecting fetal DNA in maternal blood to be eligible subject matter and that the patent was valid and infringed. [read post]
10 Jul 2013, 9:31 pm
This Complaint alleges that: Defendant, through its DNA Traits division, began offering its BRCA1 and BRCA2 analysis as part of its testing menu on... [read post]
13 Apr 2016, 8:30 am
Sequenom, Inc. commercialized the method as its MaterniT21 prenatal diagnostic test. [read post]
13 Apr 2016, 8:30 am
Sequenom, Inc. commercialized the method as its MaterniT21 prenatal diagnostic test. [read post]
26 Feb 2017, 11:01 am
Furry Babies Stratford Square, Inc., No. 13-3592, slip op. at 9 (Ill. 18th Jud. [read post]
13 Nov 2013, 8:40 pm
Pfizer Inc., No. 2012-1345 (Fed. [read post]
22 Jun 2021, 1:27 am
In 18 June 2021, a Full bench of the Federal Court of Australia (Middleton, Nicholas, and Burley JJ) unanimously upheld a decision of a single judge of the court (Beach J), finding that a method of detecting cell-free foetal DNA (cffDNA) in maternal blood serum comprises patent-eligible subject matter (i.e. a ‘manner of manufacture’) under Australian law: Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101. [read post]
22 Jun 2021, 1:27 am
In 18 June 2021, a Full bench of the Federal Court of Australia (Middleton, Nicholas, and Burley JJ) unanimously upheld a decision of a single judge of the court (Beach J), finding that a method of detecting cell-free foetal DNA (cffDNA) in maternal blood serum comprises patent-eligible subject matter (i.e. a ‘manner of manufacture’) under Australian law: Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101. [read post]
11 Jan 2016, 4:36 pm
Sequenom and Denies Rehearing En BancIn June, the Federal Circuit decided Ariosa Diagnostics, Inc. v. [read post]
